Lineage Cell Therapeutics, Inc. Deferred Income Tax Assets, Net
Lineage Cell Therapeutics, Inc. (LCTX) had Deferred Income Tax Assets, Net of $5.80 million as of 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Balance Sheet › Assets › Assets, Noncurrent
us-gaap:DeferredIncomeTaxAssetsNet · last filed 2026-08-06
- 2026-06-30: Deferred Income Tax Assets, Net $5.80M.
- 2026-03-31: Deferred Income Tax Assets, Net $5.80M.
- 2025-12-31: Deferred Income Tax Assets, Net $5.80M.
- 2024-12-31: Deferred Income Tax Assets, Net $0.00.
| Period end | Deferred Income Tax Assets, Net |
|---|---|
| 2026-06-30 | $5.80M 10-Q · filed 2026-08-06 |
| 2026-03-31 | $5.80M 10-Q · filed 2026-05-12 |
| 2025-12-31 | $5.80M 10-Q · filed 2026-08-06 |
| 2024-12-31 | $0.00 10-K · filed 2026-03-05 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Aligos Therapeutics, Inc. (ALGS) | United States | $0.238B | -0.47 |
| SUTRO BIOPHARMA, INC. (STRO) | United States | $0.260B | -3.05 |
| Protalix BioTherapeutics, Inc. (PLX) | $0.221B | 9.87 | |
| ANAVEX LIFE SCIENCES CORP. (AVXL) | United States | $0.218B | -18.37 |
| Alector, Inc. (ALEC) | United States | $0.213B | -1.90 |
| Invivyd, Inc. (IVVD) | United States | $0.270B | -2.42 |
| PALISADE BIO, INC. (PALI) | United States | $0.275B | -11.41 |
| Compass Therapeutics, Inc. (CMPX) | United States | $0.204B | -5.35 |
| Lexeo Therapeutics, Inc. (LXEO) | United States | $0.278B | -4.19 |
| FATE THERAPEUTICS INC (FATE) | United States | $0.280B | -2.51 |